Related Experiment Video
Updated: May 8, 2026
06:38
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Sequencing therapy in metastatic renal cell cancer
Bernard Escudier1, Martin Gore
1Institut Gustave Roussy, 94805 Villejuif, France. Bernard.Escudier@igr.fr
Seminars in Oncology
|August 27, 2013
Summary
Sequencing vascular endothelial growth factor (VEGF)-targeted therapies and mammalian target of rapamycin (mTOR) inhibitors offers benefits in metastatic renal cancer, but optimal treatment order is unclear due to a lack of biomarkers.
Area of Science:
- Oncology
- Medical Research
Background:
- Metastatic renal cancer treatment involves targeted therapies.
- Sequential use of vascular endothelial growth factor (VEGF)-targeted therapies or combination with mammalian target of rapamycin (mTOR) inhibitors is established.
- Optimal sequencing strategies are not yet defined.
Purpose of the Study:
- To review current data on treatment sequencing in metastatic renal cancer.
- To describe available treatment options for patients.
Main Methods:
- Review of existing clinical data and literature.
- Analysis of treatment sequences and outcomes.
- Discussion of biomarker-driven decision-making.
Main Results:
- Switching between VEGF-targeted therapies is beneficial.
- Switching between VEGF-targeted therapies and mTOR inhibitors is beneficial.
- Biomarkers for optimal sequencing are currently lacking.
Conclusions:
- Current data supports sequential use of targeted therapies in metastatic renal cancer.
- Further research is needed to identify biomarkers for personalized treatment sequencing.
- Treatment decisions currently rely on available data and clinical judgment.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...